These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25292425)

  • 1. The use of biomarkers in human pharmacology (Phase I) studies.
    Cohen AF; Burggraaf J; van Gerven JM; Moerland M; Groeneveld GJ
    Annu Rev Pharmacol Toxicol; 2015; 55():55-74. PubMed ID: 25292425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to the theme "Precision medicine and prediction in pharmacology".
    Insel PA; Amara SG; Blaschke TF
    Annu Rev Pharmacol Toxicol; 2015; 55():11-4. PubMed ID: 25562643
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems pharmacology to predict drug toxicity: integration across levels of biological organization.
    Bai JP; Abernethy DR
    Annu Rev Pharmacol Toxicol; 2013; 53():451-73. PubMed ID: 23140241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying predictive features in drug response using machine learning: opportunities and challenges.
    Vidyasagar M
    Annu Rev Pharmacol Toxicol; 2015; 55():15-34. PubMed ID: 25423479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies.
    Lesko LJ; Atkinson AJ
    Annu Rev Pharmacol Toxicol; 2001; 41():347-66. PubMed ID: 11264461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of medicines in older adults: Can we do better during clinical development?
    Saeed MA; Vlasakakis G; Della Pasqua O
    Clin Pharmacol Ther; 2015 May; 97(5):440-3. PubMed ID: 25676612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers-A General Review.
    Aronson JK; Ferner RE
    Curr Protoc Pharmacol; 2017 Mar; 76():9.23.1-9.23.17. PubMed ID: 28306150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
    Vinks AA; Emoto C; Fukuda T
    Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The animal rule: The role of clinical pharmacology in determining an effective dose in humans.
    Bergman KL
    Clin Pharmacol Ther; 2015 Oct; 98(4):365-8. PubMed ID: 26082064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology for the geriatric surgical patient.
    Then J; Tisherman SA
    Surg Clin North Am; 2015 Feb; 95(1):139-47. PubMed ID: 25459548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.
    Deaton AM; Fan F; Zhang W; Nguyen PA; Ward LD; Nioi P
    Toxicol Sci; 2019 Feb; 167(2):593-603. PubMed ID: 30346593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.